Search

Your search keyword '"Samantha Bersani"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Samantha Bersani" Remove constraint Author: "Samantha Bersani"
35 results on '"Samantha Bersani"'

Search Results

1. Reporting tumor molecular heterogeneity in histopathological diagnosis.

2. Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma.

3. Supplementary Table 3 from A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics

4. Supplementary Methods, Figure Legends, Table Legends from A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics

5. Supplementary Table 1 from A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics

6. Supplementary Figures 1 - 6 from A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics

7. Supplementary Table 2 from A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics

8. Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles

9. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?

10. Non-functional pancreatic neuroendocrine tumours

11. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

12. Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies

13. Chromosome 3p alterations in pancreatic endocrine neoplasia

14. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases

15. Diagnostic Usefulness of Fluorescent Cytogenetics in Differentiating Chromophobe Renal Cell Carcinoma From Renal Oncocytoma

16. Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification

17. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics

18. Erratum: Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours

19. Reporting tumor molecular heterogeneity in histopathological diagnosis

20. Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract: Targeted Next Generation Sequencing Suggests a Monoclonal Origin of the Two Components

21. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater

22. A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status

23. Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma

24. Expression of the Antiapoptotic Protein BAG3 Is a Feature of Pancreatic Adenocarcinoma and Its Overexpression Is Associated With Poorer Survival. Turco MC: Corresponding Author

25. Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries

26. Suitability of infiltrative lobular breast carcinoma for anti-human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meeting

27. Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy

28. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type

29. Genotypic Intratumoral Heterogeneity in Breast Carcinoma with HER2/neu Amplification Evaluation According to ASCO/CAP Criteria

30. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy

31. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior

32. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models

33. TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)

34. Prognostic impact of FHIT, APC, and HER2 status in resected gastric cancer: A clinical-biological risk stratification model

35. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.

Catalog

Books, media, physical & digital resources